{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:46:58Z","timestamp":1778179618385,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The combination of dapagliflozin and metformin is commonly used as an initial therapy for patients with type 2 diabetes mellitus (T2DM) with high glycated hemoglobin (HbA1c) levels. Although bioequivalence has been established for the fixed-dose combination (FDC) of dapagliflozin\/metformin extended-release (XR) compared to the co-administration of dapagliflozin and metformin XR, it remains uncertain whether the efficacy of dapagliflozin\/metformin FDC is comparable to that of co-administration. Additionally, it is still unclear whether fixed-dose combinations offer advantages in terms of patient adherence and satisfaction. This study aims to compare the dapagliflozin\/metformin XR FDC with co-administration of dapagliflozin and metformin XR for efficacy in terms of glycemic control, patient satisfaction, quality of life and adherence in Chinese patients with newly diagnosed T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multicenter, randomized, non-inferiority, open-label clinical trial enrolled 632 patients with T2DM (HbA1c 7.5\u201310%) in 35 research centers in China. After enrollment, the patients will be randomly assigned to receive either FDC treatment (10 mg dapagliflozin and 1000 mg metformin XR) or co-administered 10 mg dapagliflozin and 1000 mg metformin XR tablets for 24 weeks. The primary endpoint was the change in HbA1c level from baseline after 24 weeks of treatment. Secondary endpoints included the proportion of patients achieving HbA1c below 7.0%, absolute changes in fasting plasma glucose and postprandial glucose from baseline to week 24, the difference in patient satisfaction measured with the diabetes treatment satisfaction questionnaire, medication usage measured with adherence to refills and medications scale for diabetes between the two groups at week 24, change from baseline in diabetes quality of life questionnaire score at week 12 and week 24, and safety. Continuous glucose monitoring will also be used to evaluate the benefits of FDC compared with co-administration on glycemic variability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study, as the first of its kind, will provide comparative data on the efficacy of the dapagliflozin\/metformin XR FDC and co-administration of dapagliflozin and metformin XR in terms of glycemic control, patient satisfaction, quality of life and adherence. These data will help clinicians make more informed decisions for patients with type 2 diabetes and may improve medication burden, treatment adherence, and satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1690339","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:22:25Z","timestamp":1762233745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Study protocol of a multicenter, randomized, non-inferiority, open-label study investigating the efficacy of a fixed-dose combination regimen of dapagliflozin\/metformin versus co-administered dual therapy based on glycemic control, satisfaction and adherence in patients with newly diagnosed type 2 diabetes mellitus"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiaxuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study","volume":"369","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin\u2014mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1080","article-title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline","volume":"377","author":"Li","year":"2022","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.008387","article-title":"Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks","volume":"295","author":"Perry","year":"2020","journal-title":"J Biol Chem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12233","article-title":"Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis","volume":"16","author":"Phung","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32131-2","article-title":"Glycemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicenter, randomized, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3760\/cma.j.cn115791-20241203-00705","article-title":"Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition)","volume":"17","author":"Society","year":"2025","journal-title":"Chin J Diabetes Mellitus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm \u2013 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn311282-20230216-00072","article-title":"Metabolic disease management guideline for national metabolic management center (2nd edition)","volume":"39","year":"2023","journal-title":"Chin J Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12651","article-title":"Adherence to diabetes medication: a systematic review","volume":"32","author":"Krass","year":"2015","journal-title":"Diabetes Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080238","article-title":"Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy","volume":"66","author":"Benner","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: A meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.004","article-title":"Bioequivalence, Food Effect, and Steadyadyce: A Meta-Analysis. n adherence in patin Extended\u2010release Fixed\u2010dose Combination Tablets Relative to Single\u2010component Dapagliflozin and Metformin Extended\u2010release Tablets in Healthy Subjects","volume":"37","author":"Chang","year":"2015","journal-title":"Clin Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/1753-0407.12357","article-title":"Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial","volume":"8","author":"Yang","year":"2016","journal-title":"J Diabetes"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1988","article-title":"Dapagliflozin plus saxagliptin add-on therapy compared with insulin in patients with type 2 diabetes poorly controlled by metformin with or without sulfonylurea therapy: A randomized clinical trial","volume":"42","author":"Vilsb\u00f8ll","year":"2019","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_514","article-title":"Glycemic control and vascular complications in diabetes mellitus type 2","volume":"1307","author":"Maranta","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global etiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1002\/dmrr.279","article-title":"Patient perceptions of diabetes and diabetes therapy: assessing quality of life","volume":"18","author":"Bradley","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03846-9","article-title":"Quality of life, diabetes-related stress and treatment satisfaction are correlated with glycemia risk index (GRI), time in range and hypoglycemia\/hyperglycemia components in type 1 diabetes","volume":"86","author":"D\u00edaz-Soto","year":"2024","journal-title":"Endocrine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/13548506.2016.1147055","article-title":"The effect of diabetes knowledge and attitudes on self-management and quality of life among people with type 2 diabetes","volume":"22","author":"Kueh","year":"2016","journal-title":"Psychol Health Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.diabres.2013.09.010","article-title":"The ARMS-D out performs the SDSCA, but both are reliable, valid, and predict glycemic control","volume":"102","author":"Mayberry","year":"2013","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1690339\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:22:27Z","timestamp":1762233747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1690339\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":30,"alternative-id":["10.3389\/fendo.2025.1690339"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1690339","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"article-number":"1690339"}}